KANGHUA HEALTH3689.HKValuation Analysis
Based on the blended 10-year P/E and P/B percentiles, the stock currently sits in the “Deeply Undervalued” zone.
As of Oct 16, 2026, KANGHUA HEALTH (3689.HK) trades at a P/E of 5.74x, P/B of 0.36x, P/S of 0.28x, and a dividend yield of 10.10%.
Longitudinal percentile comparison: P/E sits at the 16th percentile over the trailing 10Y window (vs. 36th percentile over 3Y); P/B sits at the 9th percentile over the trailing 10Y window (vs. 12th percentile over 3Y); P/S sits at the 13th percentile over the trailing 10Y window (vs. 19th percentile over 3Y).
Cross-sectional valuation: its P/E ranks at the 10th percentile within its industry and the 22nd percentile across the broader market.
Shareholder return highlight: Total Shareholder Yield is 10.10%, ranking at the 96th percentile over the trailing 20Y window.
Cross-checking P/E against P/B, the two percentiles sit within 6.2 points of each other — a consistent signal from both angles. The P/E percentile sits lower within its industry than across the market as a whole — relatively cheaper next to direct peers. Shareholder returns here are driven almost entirely by cash dividends, with minimal contribution from buybacks. KANGHUA HEALTH operates in the Other Pharmaceuticals and Medical Services sector. Data refreshes weekly and is for reference only, not investment advice.
Also listed as: HKG: 3689 · SEHK: 3689 · 3689
Want the full picture on whether KANGHUA HEALTH (3689.HK) is under- or over-valued? See the full 3Y / 5Y / 10Y / 20Y P/E, P/B, P/S, Dividend Yield & Total Shareholder Yield percentile matrix and the interactive ECharts trend chart on this page.
Historical Percentiles by Metric
| Metric | Current | Market Percentile | Industry Percentile | 3Y Pctl | 5Y Pctl | 10Y Pctl | 20Y Pctl |
|---|---|---|---|---|---|---|---|
| P/E (TTM) | 5.74 | ||||||
| P/B (MRQ) | 0.36 | ||||||
| P/S (TTM) | 0.28 | ||||||
| Dividend Yield | 10.10% | ||||||
| Buyback + Div Yield | 10.10% |